SLN · Silence Therapeutics PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $422.0K | - | $1.50M | $224.0K | $15.70M | - | - | - | - |
| Cost of Revenue | $11.0K | - | $3.64M | $85.0K | $2.80M | - | - | - | - |
| Gross Profit | $411.0K | - | $95.0K | ($2.58M) | $12.90M | - | - | - | - |
| R&D | $9.12M | - | $20.16M | $17.65M | $11.85M | - | - | - | - |
| SG&A | $7.03M | - | $7.70M | $7.01M | $6.63M | - | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - |
| D&A | $72.0K | - | - | - | $88.0K | - | - | - | - |
| Operating Income | ($15.74M) | - | ($26.24M) | ($23.96M) | ($5.58M) | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $1.0K | $10.0K | $244.0K | - | - | - | - |
| Net Income | ($14.96M) | - | ($20.96M) | ($19.75M) | ($2.31M) | - | - | - | - |
| EPS - Basic | ($0.11) | - | ($0.25) | ($0.19) | ($0.02) | - | - | - | - |
| EPS - Diluted | ($0.11) | - | ($0.25) | ($0.14) | ($0.02) | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.66M | $11.28M | $82.03M | $41.74M | $64.89M | $121.33M | $68.79M | - | - |
| Accounts Receivable | $0 | $0 | $28.0K | $85.0K | $41.0K | $972.0K | $290.0K | - | - |
| Inventory | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | $4.41M | - | - | - | $3.70M | $3.35M | - | - |
| Current Assets | $102.85M | $118.66M | $133.63M | $148.55M | $169.79M | $187.37M | $103.15M | - | - |
| Total Assets | $115.12M | $131.44M | $146.79M | $165.23M | $185.30M | $202.63M | $119.45M | - | - |
| Current Liabilities | $10.46M | $13.61M | $17.38M | $14.77M | $19.26M | $16.82M | $22.34M | - | - |
| Long-term Debt | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $65.72M | $69.14M | $72.73M | $71.08M | $72.56M | $68.61M | $97.45M | - | - |
| Stockholders' Equity | $49.40M | $62.30M | $126.70M | $94.16M | $156.76M | $134.02M | $21.99M | $27.22M | $12.37M |
| Retained Earnings | ($577.53M) | ($562.57M) | ($550.80M) | ($529.84M) | ($502.54M) | ($474.04M) | ($431.89M) | - | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($15.60M) | - | - | - | ($9.14M) | - | - | - | - |
| Investing Cash Flow | $10.00M | - | - | - | ($49.91M) | - | - | - | - |
| Financing Cash Flow | $0 | - | - | - | $133.02M | - | - | - | - |
| CapEx | $0 | - | - | - | $0 | - | - | - | - |
| Free Cash Flow | ($15.60M) | - | - | - | ($9.14M) | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross margin | 97.4% | - | 6.3% | -1150.4% | 82.2% | - | - | - | - |
| Operating margin | -3729.1% | - | -1751.9% | -10697.8% | -35.6% | - | - | - | - |
| EBITDA margin | -3712.1% | - | - | - | -35.0% | - | - | - | - |
| Net margin | -3544.3% | - | -1399.1% | -8819.2% | -14.7% | - | - | - | - |
| Free cash flow margin | -3697.4% | - | - | - | -58.2% | - | - | - | - |
| FCF / Net income | 1.04 | - | - | - | 3.95 | - | - | - | - |
| R&D / Revenue | 2161.6% | - | 1345.7% | 7878.1% | 75.5% | - | - | - | - |
| SG&A / Revenue | 1664.9% | - | 513.8% | 3129.0% | 42.3% | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - |
| Return on assets | -13.0% | - | -14.3% | -12.0% | -1.2% | - | - | - | - |
| Return on equity | -30.3% | - | -16.5% | -21.0% | -1.5% | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - |
| Liquidity | |||||||||
| Current ratio | 9.83 | 8.72 | 7.69 | 10.06 | 8.81 | 11.14 | 4.62 | - | - |
| Quick ratio | 9.83 | 8.72 | 7.69 | 10.06 | 8.81 | 11.14 | 4.62 | - | - |
| Cash ratio | 0.54 | 0.83 | 4.72 | 2.83 | 3.37 | 7.21 | 3.08 | - | - |
| Leverage | |||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.33 | 2.11 | 1.16 | 1.75 | 1.18 | 1.51 | 5.43 | - | - |
| Liabilities / Assets | 0.57 | 0.53 | 0.50 | 0.43 | 0.39 | 0.34 | 0.82 | - | - |
| Efficiency | |||||||||
| Asset turnover | 0.00 | - | 0.01 | 0.00 | 0.08 | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 0d | - | 7d | 139d | 1d | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - |
| Valuation | |||||||||
| P / E | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - |
| Growth | |||||||||
| Revenue growth (YoY) | -97.3% | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -96.8% | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -182.0% | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | -546.9% | - | - | - | - | - | - | - | - |
| EPS growth (YoY) | -450.0% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -70.7% | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -68.5% | -53.5% | - | - | - | 509.4% | -19.2% | 120.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$559.0K totalResearch Collaboration Income$559.0K · 100.0%
Geographic
$559.0K totalGB$559.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Silence Therapeutics plc against the 5 most active filers in the same SIC group.